['There is recent in vitro and in vivo evidence that somatostatin receptor sst2 antagonists are better tools to target neuroendocrine tumors (NET) than sst2 agonists. Indeed, antagonists bind to a greater number of sst2 sites than agonists. Whether sst2 antagonists could be used successfully to target non-NET tumors, expressing low sst2 density, is unknown. Here, we compare quantitatively ', 'In vitro receptor autoradiography was performed with ', 'In general, '] Does hIGHLY INCREASED 125I-JR11 ANTAGONIST BINDING IN VITRO reveal NOVEL INDICATIONS FOR SST2 TARGETING IN HUMAN CANCERS?